AMLX · Amylyx Pharmaceuticals, Inc.

Track AMLX — free

$34.84 -2.34 (-6.29%)

Russell 2000 member Rebalance outlook locked

Market Cap

$4.13B

111.42M

Up next

Next earnings call

Nov 5, 2026 Est · unconfirmed · in 10 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 6, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Ask ALVIS about this →

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 14.5 · calm Equity put/call 0.39

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +129%

above

Price vs 50-day avg +68%

above

RSI (14) 76

overbought

MACD trend Positive

52-week position 92%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +79%

trailing

6-month return +168%

trailing

YTD return +208%

this year

Relative strength +154%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $22 › 200d $16 — 50d above 200d

Institutional flow Accumulating

+19% holders QoQ · +50 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

12.05% of float · ▲ +0.2% MoM · 7.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

206 holders — near 3-yr high, broad support

Squeeze score 77

high risk · 0–100

Fundamentals

Strong

Revenue growth +1613%

Y/Y

EPS growth +65%

Y/Y

Free cash flow $-123.5M

Balance sheet $226.7M

net cash

Quant / Vol

risk profile

Very High

Volatility 88%

annualized · 1-yr

Max drawdown −31%

past year

ATR 6.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Jun 30, 2023

Gross to net discounts · going forward 12% – 15%

COGS as a percentage of sales · going forward 6% – 10%

Prior guidance period ended · from the Earnings Call filed Nov 9, 2023

Research and development expenses · fourth quarter $35M – $40M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 2 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+129% Bullish

Price vs 50-day avg

+68% Bullish

RSI (14)

76 Bearish

MACD trend

Positive Bullish

52-week position

92% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $22 › 200d $16 — 50d above 200d

Institutional flow Accumulating

+19% holders QoQ · +50 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

12.05% of float · ▲ +0.2% MoM · 7.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

206 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $9 Now $37 · 92% Range high $40

vs 200-day avg +129% vs 50-day avg +68%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
AMLX Amylyx Pharmaceuticals, Inc. this stock	$4.13B	+207.8%	+1612.9%	—	12.0%
JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR	$66.37B	—	—	—	0.0%
TAK Takeda Pharmaceutical Co Ltd	$58.22B	+15.7%	—	—	0.1%
GALDY Galderma Group AG/ADR	$49.41B	+2.5%	—	—	0.0%
TEVA Teva Pharmaceutical Industries Ltd	$44.19B	+20.5%	+4.3%	62.2	3.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

206

% held: 103.7%
Net QoQ: +900.3K sh
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

190

View

Short & Settlement

Short Interest Rising

Shares short

13.4M

Days to cover: 7.1d
Change: +23.4K sh

View

Short Volume

Short vol %

47%

As of: Aug 27, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $409
As of: Jul 28, 2026

View

Off-Exchange

Off-exchange %

47.2%

Week of: Jul 20, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Buy

Member

Christopher L. Jacobs

Amount: $1.0K–$15.0K
Traded: Oct 12, 2022

View

Financials

Revenue (FY)

Net income (FY): $-144.7M
EPS diluted: $-1.53

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 20, 2026
This year: 13

View

Proposed Sales

Value

$536.4K

Shares: 30.0K
Filed: Jul 9, 2026

View

Exempt Offerings

Offering

$30.0M

Filed: Jul 1, 2020

View

Earnings & Events

Earnings Calls

Last call

Aug 6, 2026

View

Performance

	5D	20D	120D	MTD	YTD
AMLX	-6.3%	+79.2%	+168.5%	+83.1%	+207.8%
SPY	+1.1%	+4.0%	+14.7%	+3.2%	+13.1%
vs SPY	-7.4%	+75.2%	+153.8%	+79.8%	+194.7%

Key facts CIK 1658551 CUSIP 03237H101 13F (30d) 187 filings 187 filers Visit website Investor relations

AMLX · Amylyx Pharmaceuticals, Inc.

Price & Indicators

Up next

AI Brief

Equibles Rating

Guidance & track record

Technicals

Versus peers

At a glance

Performance